These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36288089)

  • 21. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience.
    Steggerda RC; Damman K; Balt JC; Liebregts M; ten Berg JM; van den Berg MP
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1227-34. PubMed ID: 25326737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of concomitant surgical interventions on outcomes of septal myectomy in obstructive hypertrophic cardiomyopathy.
    Altibi AM; Sapru A; Ghanem F; Zhao Y; Alani A; Cigarroa J; Nazer B; Song HK; Masri A
    Int J Cardiol; 2024 Apr; 400():131790. PubMed ID: 38242508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender-Based Outcome Discrepancies in Patients Who Underwent Alcohol Septal Ablation or Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.
    Saravanabavanandan R; Jaimalani A; Khan MAN; Riaz S; Mangas GM; Ahsan SM; Posani S; Patel T; Fawad M; Al-Tawil M
    Am J Cardiol; 2023 Dec; 208():134-142. PubMed ID: 37839170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.
    Bytyçi I; Nistri S; Mörner S; Henein MY
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32977442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy.
    Cavigli L; Fumagalli C; Maurizi N; Rossi A; Arretini A; Targetti M; Passantino S; Girolami F; Tomberli B; Baldini K; Tomberli A; Antoniucci D; Yacoub MH; Marchionni N; Stefano PL; Cecchi F; Olivotto I
    Int J Cardiol; 2018 Dec; 273():155-161. PubMed ID: 30213605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.
    Liebregts M; Vriesendorp PA; Mahmoodi BK; Schinkel AF; Michels M; ten Berg JM
    JACC Heart Fail; 2015 Nov; 3(11):896-905. PubMed ID: 26454847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy.
    Tang W; Liu M; Li J; Chang R; Su C; Zhang X; Wang L
    Rev Cardiovasc Med; 2022 Dec; 23(12):391. PubMed ID: 39076650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alcohol septal ablation: A useful tool in our arsenal against hypertrophic obstructive cardiomyopathy.
    Savarimuthu S; Harky A
    J Card Surg; 2020 Aug; 35(8):2017-2024. PubMed ID: 32652778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy.
    Sedehi D; Finocchiaro G; Tibayan Y; Chi J; Pavlovic A; Kim YM; Tibayan FA; Reitz BA; Robbins RC; Woo J; Ha R; Lee DP; Ashley EA
    J Cardiol; 2015 Jul; 66(1):57-62. PubMed ID: 25238885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy.
    Zheng X; Yang B; Hui H; Lu B; Feng Y
    Front Cardiovasc Med; 2022; 9():900469. PubMed ID: 35694661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of surgical septal myectomy for obstructive hypertrophic cardiomyopathy after previous septal reduction therapy.
    Qamar Y; Schaff HV; Castro-Varela A; Cui H; Dearani JA; Geske JB; Eleid MF; Lee AT; Lahr B; Ommen SR
    J Thorac Cardiovasc Surg; 2024 May; ():. PubMed ID: 38750691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Septal Reduction Therapy on Acute Cardiovascular Events and All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy.
    Morita SX; Zhao Y; Hasegawa K; Fifer MA; Maurer MS; Reilly MP; Takayama H; Shimada YJ
    Int Heart J; 2021 Sep; 62(5):1035-1041. PubMed ID: 34544977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction.
    Zhu C; Tang B; Cui H; Wang S; Xiao M; Chen Z; Meng Y; Zhao S; Song Y; Yu Q; Wang S
    J Card Surg; 2019 Jul; 34(7):533-540. PubMed ID: 31111576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States.
    Butzner M; Rowin E; Yakubu A; Seale J; Robertson LA; Sarocco P; Maron MS
    J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Septal Myectomy in Hypertrophic Cardiomyopathy: National Outcomes of Concomitant Mitral Surgery.
    Holst KA; Hanson KT; Ommen SR; Nishimura RA; Habermann EB; Schaff HV
    Mayo Clin Proc; 2019 Jan; 94(1):66-73. PubMed ID: 30611455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy.
    Patlolla SH; Schaff HV; Nishimura RA; Eleid MF; Geske JB; Ommen SR
    J Am Heart Assoc; 2023 Jan; 12(1):e026661. PubMed ID: 36565202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy.
    Altibi AM; Ghanem F; Zhao Y; Elman M; Cigarroa J; Nazer B; Song HK; Masri A
    J Am Heart Assoc; 2023 May; 12(10):e028693. PubMed ID: 37183831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.